Abstract YO10
Case summary
A 22y/female
No comorbidities
No family history of any malignancy
Presented with complaints of mass P/R from December 2014
Initially patient was on alternative medication with an opinion of hemorrhoids
In October 2015 in view of increased symptoms got evaluated and U/W Sigmoidoscopy and found to have growth
2/12/15 U/W Polypectomy
HPR S/O Follicular dendritic cell sarcoma with negative margins
21/12/15 CECT S/O no abnormality , though patient was planned for surgery with revision of margins opted for observation
July 2016 Patient is asymptomatic and on follow up found to have (USG and CT further) multiple liver metastases with Bx consistent with same.
Received 4# CHOP till 17/11/16
Dec 2016 CT S.O Increase in number and size of hepatic metastases
Started on Gemcitabine+Docetaxel 6# with interim assessment S.O partial response and further mainatined.
11/9/17 U.W RFA of Segment VIII of right lobe and Segment III of left lobe of liver.
Received 2# more Gemciatbine+Docetaxel till 20/10/17
November 2017 PET CT S/O Complete metabolic response and kept on observation
9/3/18 Evaluated for abdominal discomfort and S.O liver lesions in segment IVb and Segment V lesions
15/3/18 IVb and V lesion coiling was done and kept on observation
May 2018 Significant increase in number and size of lesions and was started on Tab.Capecitabine 500mg BD+Tab.Sorafenib 400mg BD
July 2018 Response assessment was done S/O increase in size of lesions with maximum lesion size increased from 3.9----->6 cms
Started on Tab.Pazopanib +Tamoxifen
October 2018 response assessment was done S/O Partial response with decrease in size and enhancement
27/12/18 U/W resection of liver IVb/V segments and Pazopanib+Tamoxifen were continued as an adjuvant from January 2019 to April 2019
Lost to follow up for 2 months and stopped medications from 2 months
13/6/19 Asymptomatic but CT S/O two new lesions in liver segment VII 2.1x 1.4cms and 1.2x1.2 cms were noted.
CURRENT STATUS : Restarted on Tab.Pazopanib 400mg BD and planned for RFA further
Clinical trial identification
Editorial acknowledgement
Resources from the same session
YO20 - Can "Superman" have Chronic Myelomonocytic Leukemia?
Presenter: Alexander Luchinin
Session: Poster display session
Resources:
Abstract
YO21 - Sanctuary Site Central Nervous System Relapse-Refractory DLBCL Responding to Nivolumab and Lenalidomide.
Presenter: Irappa Madabhavi
Session: Poster display session
Resources:
Abstract
YO22 - External Auditory Canal Mass: A Case Series of Squamous Cell Carcinoma
Presenter: Mel Valerie Cruz-Ordinario
Session: Poster display session
Resources:
Abstract
YO23 - Soft tissue Giant cell tumor presented as Nasopharyngeal mass: A case report
Presenter: Emmelyn Buenacosa-Nepucpan
Session: Poster display session
Resources:
Abstract
YO25 - Hyperprogression after pembrolizumab in recurrent oropharyngeal cancer and the use of nab-paclitaxel as salvage treatment- A case report.
Presenter: Izzati Rosli
Session: Poster display session
Resources:
Abstract
YO26 - Exacerbation of radiation necrosis around the radiotherapy-pretreated brain metastases site after immune checkpoint inhibitors.
Presenter: Minako Nishio
Session: Poster display session
Resources:
Abstract
YO27 - Comparative Study Of 20Gray/5Fraction And 30Gray/10 Fraction Whole Brain Radiation In Brain Metastasis
Presenter: Pradip Bhandari
Session: Poster display session
Resources:
Abstract
YO28P - The response to anaplastic lymphoma kinase (ALK) inhibitor in metastatic anaplastic thyroid carcinoma (ATC)
Presenter: Nur Faizah Ab Muin
Session: Poster display session
Resources:
Abstract
YO29 - Acute kidney injury secondary to bilateral renal artery tumor thrombosis in a case of posterior mediastinal undifferentiated sarcoma: case report
Presenter: Ritsu Ibusuki
Session: Poster display session
Resources:
Abstract
YO30 - Follicular dendritic cell sarcoma of the tonsil- a multimodality approach
Presenter: Rich Ericson King
Session: Poster display session
Resources:
Abstract